Blockade of renin-angiotensin system (RAS) (fosinopril, ramipril, lisinopril, perindopril) and ARB II (valsartan, losartan, telmisartan, candesartan with-ramipril, lisinopril, perindopril, valsartan, losartan, telmisartan, candesartan. 
main classes of antihypertensive drugs: angiotensin-converting-enzyme inhibitors (ACEIs), Angiotensin II Receptor Blocker II (ARB), calcium channel blocking agents (CCBA), beta-blocking agent (BBA), diuretics [34] . The change in RAAS activity is possible on the background of antihypertensive therapy. One way of reducing the activity of RAAS is the suppression of synthesis of angiotensin II [41, 42] .
The purpose of this study is to determine, from the perspective of a pharmacoeconomic analysis of preemptive medications used for the treatment of hypertension based on the comparison between cost and efficiency, safety and quality of life in the treatment of drugs of two classes of antihypertensive drugs ACEIs: Fosinopril, Ramipril, Lisinopril, Perindopril and ARB: Losartan, Valsartan, Candesartan, Telmisartan.
Objectives:
1. To explore an informational material (scientific publications, guidelines for physicians, tutorials) about modern methods of treatment of patients with arterial hypertension.
To determine indicators of clinical efficacy of drug therapy of hypertension
and types of cost, their use in comparative pharmacoeconomic study is most appropriate. 3. To calculate the costs for pharmacotherapy of ACEIs -Fosinopril, Ramipril, Lisinopril, Perindopril, ARB -Losartan, Valsartan, Candesartan, Telmisartan) 4. To conduct a pharmacoeconomic cost-effectiveness analysis and the budget impact analysis of the use of ACEIs drugs -Fosinopril, Ramipril, Lisinopril, Perindopril, ARB -Losartan, Valsartan, Candesartan, Telmisartan in the treatment of hypertension and to determine the optimal position of pharmacoeconomics of medical technology in the treatment of hypertension
Pecularities of the study
In the first phase, to identify differences between the drugs ACEI and ARBS II, an analysis was conducted of various information sources: pharmacoeconomic and clinical research in foreign databases (DB) -in Pubmed, Medlink, etc. keyword: "angiotensin converting enzyme inhibitors, blockers of receptors of angiotensin-II, renin-angiotensin-aldosterone system, fosinopril, ramipril", "lisinopril", "perindopril", "valsartan", "losartan", "telmisartan", "candesartan", "cardiovascular diseases", "pharmacoeconomics", "cost analysis", "costeffectiveness "analysis", "budget impact", "stroke", "myocardial infarction", "arterial hypertension". Also, the information search was conducted in the Russian-language databases, Russian medicine, Central scientific medical library of the First MGMU named after I. M. Sechenov, scientific electronic library elibrary. ru, CyberLink and free search engine such as Yandex, Google etc. Information search in Russian database included the following keywords: ACEIs, ARB, RAAS, fosinopril, ramipril, lisinopril, perindopril, valsartan, losartan, telmisartan, candesartan, hypertension, myocardial infarction, stroke, cardiovascular diseases , analysis of the "impact on budget", the cost-minimization analysis, cost analysis, pharmacoeconomics. In the search process, corresponding to the inquiry, it was found 113 publications. Next, duplicate publications and studies not related to the problem of treatment of hypertension with use of antihypertensive drugs were excluded; and was not included in further analysis of randomized clinical trials (RCTS) to compare drugs were evaluated in combination with other antihypertensive agents. The level of evidence was determined according to the scales assessing the levels of evidence results RCTS of drugs and the assessment of levels of credibility of evidence RCT LS. In the first place was out of the study with level of evidence A or b: the evidence summarized in the systematic review, meta-analysis, and evidence obtained in prospective RCTS, respectively. In the absence of such research was considered with a lower level of evidence. The results are summarized in a special table for analysis and subjected to peer review. Thus, after screening for detailed analysis included 22 publications (tab. 1). 
PHARMACOECONOMIC ANALYSIS OF MEDICINAL DRUG FOSINOPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION

Effectiveness analysis
For analysis of efficiency and analysis of "cost-effectiveness" on the basis of information found during the search of RCTS for each drug of the two groups of antihypertensive drugs -ACE-I (fosinopril, lisinopril, ramipril and perindopril) and ARBS II (losartan, valsartan, candesartan and telmisartan), we determined the criterion of effectiveness is the achievement of target blood pressure. In addition to the criterion of efficiency for analysis "cost-effectiveness" and cost analysis, we have identified unwanted cardiovascular events which included: THEY (fatal and nonfatal), stroke (fatal and nonfatal) and SN, as well as side effects of drug therapy such as hypotension, cough and angioedema. Data analysis of effectiveness are presented in table 2.
The performance indicator for each of the studied drugs of antihypertensive drugs groups ACEI (fosinopril, lisinopril, ramipril and perindopril) and ARBS II (losartan, valsartan, candesartan and telmisartan) was taken from pre-registration studies phase III. Data on the incidence of adverse cardiovascular events and side effects mainly from post-marketing studies phase IV [1- 24, 38] .
Cost analysis
In the present study were evaluated only direct medical costs of using medicines: perindopril, ramipril, lisinopril, losartan, valsartan, candesartan and telmisartan in comparison with the medicine fosinopril. Prices on medicines were taken from the Internet resources www.medlux.ru and www.pharmindex.ru with further calculation of the average cost of 1 mg of active substance (tab. 3).
Table 2 . Results of effectiveness analysis
INN
Achievement of target AH %
Fatal /non-fatal infarction % Heart failure % Stroke (fatal and non-fatal) % Hypotension % Cough % Angioedema, % Losartan 67,1 [14] 6,66 [12] 11,85 [12] 6,39 [12] 1,7 [13] 1 [13] 0,4 [13] Valsartan 82,7 [7] 4,82 [15] 4,63 [15] 4,21 [15] 15,1 [16] 1,7 [16] 0,2 [16] Candesartan 64 [18] 2,83 [19] 0,8 [20] 3,59 [19] 3,7 [21] 0,2 [21] 0,1 [21] Telmisartan 58 [2] 1,66 [22] 1,19 [22] 8,67 [22] 3,9 [22] 1,1 [23] 0,2 [22] Perinopril 46 [2] 4,83 [1] 0,7 N/A Ramipril 85 [4] 9,88 [3] 9 [3] 3,36 [3] 1,89 [3] 7,32 [3] N/A Lisinopril 60 [6] 2,2 [5] 1,1 [5] 1,6 [5] 0,5 [7] 7,2 [7] N/A Fosinopril 79,8 [9] 1,8 [10] 0,2 [11] 0,7 [10] 0,6 [11] 5 [10] N/A
The table below shows that the highest percentage of achievement of BP has been demonstrated in drugs: ramipril -85%, valsartan -82,7% and fosinopril -79.8 per cent. The lowest incidence of mi was drugs: telmisartan and 1.66%, fosinopril -1.8% and lisinopril was 2.2%. The lowest incidence of CH was drugs: fosinopril -0,2 %, perindopril -0.7% and candesartan and 0.8%. The lowest frequency of stroke was drugs: fosinopril -0,6%, lisinopril -1.3% of perindopril and by 1.6%. The lowest frequency of hypotension was for drugs: lisinopril -0,5%, fosinopril -0.6% and perindopril -1%. The lowest incidence of cough was drug: candesartan and 0.2%, losartan -1% and telmisartan -1,1%. The incidence of angioneurotic edema was evaluated only for drugs of group II ARBS (losartan, valsartan, candesartan and telmisartan), drug from the group of ACE inhibitors (perindopril, ramipril, lisinopril, and fosinopril) of such data in RCTS has been presented. According to the data presented in table 3 -least cost of 1 mg for studied drugs: losartan -0,38 rub., valsartan -0,61 RUB.. and fosinopril -0,73 RUB. The greatest value of 1 mg was observed in LP: ramipril -7,22 RUB., candesartan -4,75 RUB. and perindopril -2,66 RUB. www.pharmacoeconom.com Taking into account the results of information retrieval and recommendation of application guidelines, budget and planning of the health system in the treatment of hypertension, for further calculations we took the time interval in the amount of one years.
All calculations of the value of pharmacotherapy in the treatment of various conditions was based on the standards from table 4. Feature of the present cost analysis was that in addition to the basic calculation of the cost of pharmacotherapy, we also calculated the compensation cost for the treatment of cardiovascular events and adverse effects from each specific PL.
Thus, the cost of providing out-patient or emergency medical care for hypertension at each stage was 9 501 rub. and 5 228 rub. respectively; during myocardial infarction at each stage -375 255 rub. и 17 421 rub. respectively; during cardiac insufficiency -67 757 rub. and 9 526 rub. respectively; during stroke -289 715 rub. and 20 072 rub. respectively; during angioneurotic edema -27 010 rub. The results of the cost analysis are presented in table 5.
Cost-effectiveness analysis
The calculations of cost-effectiveness analysis were performed separately for each drug. The result of the analysis is represented as a cost per unit of effectiveness with the subsequent comparison of the obtained results. Calculation in accordance with the methodology, was carried out according to the formula: СЕR= (DC+IC )/Ef, where СЕR -cost-effectiveness ratio (defines costs, which are necessary for a unit of effectiveness, for example per 1 treated patient); • DC -direct costs, including direct medical and direct non-medical costs;; • IC -indirect costs;
• Ef -effectiveness (relative amount of treated patients).
After evaluating the cost and effectiveness of pharmacotherapy for AH with antihypertensive drugs values of the cost-effectiveness ratios (СER) as the ratio of total cost to percentage of patients achieved target arterial pressure level were calculated. (табл. 6). During cost-effectiveness analysis is defined that Fosinopril has the lowest CER. From table 6 it is seen that the smallest lowest CER.have the following LP: fosinopril -285, lisinopril -463 and candesartan -567.
Budget impact analysis
The next step was the implementation of budget impact analysis based on the data about the duration of treatment of patients suffering from AH, to assess the economic impact on the health care budget when choosing therapy. As part of this analysis by time horizon compared to the use of alternatives 365 days in accordance with the recommended instructions for use was analyzed. Figure 1 shows that drug fosinopril has the least total costs, therefore, the drug fosinopril comparison with the other drugs for the demonstration of economy of budgetary funds.
Next, we calculated of the transitions from different drugs to fosinopril as the drug with the lowest total cost
The results obtained demonstrate fiscal savings when transferring all patients to other LP on treatment with fosinopril. With this transfer, the cost savings will be from 5 048 rub. to 46 805 rub. a year, depending on the drug. (fig.2) .
Sensitivity analysis
For identification of the fact will be the usage of fosinopril still cost-effective under another profile of costs, the one-factor sensitivity analysis is conducted.
As variables values of the main drugs of pharmacotherapy were considered. Sensitivity analysis defines, how the change in the value of two classes of antihypertensive drugs ACEIs and ARB will affect the cost -effectiveness ratios in the treatment of hypertension.
Conclusions:
During direct costs analysis for AH therapy on the basis of current standards of rendering medical care for AH patients the total costs for two types of antihypertensive drugs were performed: fosinopril -22 751 rub. compared with other drugs: perindopril -37 795rub., ramipril -69 543rub., lisinopril -27 786rub., losartan -68 458rub., valsartan -49 042rub., candertan -36 264 rub., telmisartan-47 747rub.
Basing on the cost-effectiveness analysis it is showed that Fosinopril has pharmacoeconomic advantage 285 rub. 
